CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2023. The put-call ratio across all filers is 1.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $61,103,603 | +23.2% | 1,494,341 | +27.4% | 0.02% | +16.7% |
| Q1 2024 | $49,577,933 | +3.2% | 1,172,887 | +3.6% | 0.02% | 0.0% |
| Q4 2023 | $48,023,936 | +2329.8% | 1,132,640 | +1151.0% | 0.02% | +1700.0% |
| Q3 2023 | $1,976,488 | -31.3% | 90,540 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $2,878,267 | +75.6% | 90,540 | +34.7% | 0.00% | 0.0% |
| Q1 2023 | $1,639,008 | -22.7% | 67,200 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $2,119,488 | +11.6% | 67,200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,899,000 | +14.4% | 67,200 | +7.0% | 0.00% | 0.0% |
| Q2 2022 | $1,660,000 | -4.0% | 62,800 | +27.1% | 0.00% | 0.0% |
| Q1 2022 | $1,729,000 | -28.4% | 49,400 | -33.7% | 0.00% | 0.0% |
| Q4 2021 | $2,414,000 | +40.8% | 74,454 | +28.1% | 0.00% | 0.0% |
| Q3 2021 | $1,715,000 | +108.9% | 58,130 | +81.5% | 0.00% | – |
| Q2 2021 | $821,000 | – | 32,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |